Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex, Inc. (NASDAQ: GNPX) generates a steady flow of news as a clinical-stage gene therapy company developing treatments for cancer and diabetes. Its updates frequently center on progress in lung cancer trials with Reqorsa Gene Therapy (quaratusugene ozeplasmid) and preclinical advances in its diabetes program, GPX-002.
Investors following GNPX news can expect coverage of clinical trial milestones, such as dose-escalation results, Phase 2 expansion plans, new trial site additions, and peer-reviewed publications from studies like the Acclaim-1 and Acclaim-3 trials in non-small cell and small cell lung cancer. Company releases also highlight regulatory designations, including FDA Fast Track and Orphan Drug status for Reqorsa-based programs.
Another major news theme is preclinical and translational data. Genprex and its collaborators report findings on Reqorsa’s activity in specific lung cancer subtypes, including ALK-EML4-positive NSCLC models, as well as animal data showing TUSC2 upregulation, apoptosis induction, and survival benefits in xenograft studies. For diabetes, news often covers GPX-002 proof-of-concept data in Type 1 and Type 2 diabetes mouse and non-human primate models, including effects on beta-cell function and glucose control.
Genprex also issues corporate and regulatory announcements, such as registered direct offerings, at-the-market programs, warrant-related financings, and patent developments around Reqorsa combinations with PD-1 and PD-L1 antibodies. These items provide context on the company’s capital strategy and intellectual property position.
For readers tracking GNPX, this news stream offers insight into how Genprex’s gene therapy platforms are advancing through research, clinical development, regulatory interactions, and financing activities over time.
Genprex, Inc. (NASDAQ: GNPX) announced the launch of new branding for its upcoming oncology clinical trials combining its lead drug candidate, REQORSA™ (quaratusugene ozeplasmid), with AstraZeneca’s Tagrisso® (osimertinib) and Merck’s Keytruda® (pembrolizumab) for non-small cell lung cancer (NSCLC). The trials, branded as 'Acclaim,' aim to provide hope for NSCLC patients. Acclaim-1 targets late-stage NSCLC with mutated EGFRs, while Acclaim-2 targets low expressors of PD-L1. The trials are expected to commence in the first half of 2021.
Genprex, Inc. (NASDAQ: GNPX) announced that the FDA has conditionally accepted the proprietary name REQORSA™ for its lead drug candidate targeting non-small cell lung cancer, previously known as GPX-001. This name approval is a critical step towards marketing the therapy and enhances the brand identity of Genprex. The REQORSA drug utilizes the ONCOPREX® nanoparticle delivery system and previously received Fast Track Designation from the FDA. Final approval of the name is contingent upon successful clinical trials and FDA product candidate approval.
Genprex, Inc. (GNPX) has promoted Eric Chapdelaine to Vice President of Manufacturing, reflecting the company’s progress in scaling its manufacturing operations. This comes as Genprex prepares for upcoming Phase I/II clinical trials of its lead candidate, GPX-001, in combination with AstraZeneca’s Tagrisso for non-small cell lung cancer (NSCLC). The company received FDA Fast Track Designation for GPX-001 in January 2020, aimed at improving treatment options for patients who have progressed on prior therapies.
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, will present virtually at the Zooming with LD Micro event on October 14 at 11 a.m. ET. CEO Rodney Varner will lead the presentation followed by a Q&A session. Genprex focuses on developing technologies for cancer and diabetes patients, with its lead product candidate, GPX-001, aimed at treating non-small cell lung cancer (NSCLC). The FDA has granted GPX-001 Fast Track Designation for combination therapy with osimertinib for patients with EGFR mutations.
Genprex, Inc. (NASDAQ: GNPX) announced its participation in the upcoming Cell and Gene Meeting on the Mesa from October 12-16, 2020. Michael Redman, Executive VP and COO, will present on the company's innovative gene therapies targeting cancer and diabetes. The virtual event aims to tackle commercialization challenges in the cell and gene therapy sector, featuring on-demand presentations and live panels. Genprex's lead candidate, GPX-001, is in development for non-small cell lung cancer and received FDA's Fast Track Designation.
Genprex (NASDAQ:GNPX) announced its upcoming presentation at the LD 500 Virtual Investor Conference on September 1, 2020, at 1:20 p.m. ET. CEO Rodney Varner will discuss the company's product pipeline, highlighting GPX-001, which has received Fast Track Designation from the FDA for late-stage lung cancer treatment. The presentation will be available via live webcast on the conference and company websites. Genprex focuses on gene therapy advancements for cancer and diabetes, aiming to provide new treatment options.